Navigation Links
Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
Date:9/25/2013

OXFORD, England, September 25, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced the appointment of Justine McQuillan as its European Director of Clinical Affairs. In this newly established position, McQuillan is leading European clinical regulatory trials of GlySure's CBGM technology, which the company expects to complete this fall.

McQuillan has extensive clinical, operational and commercial experience within the MedTech industry, with expertise in the development, evaluation and validation, regulatory clearance and marketing of medical devices and supporting services. She spent eight years at Medicsight PLC, having most recently served as Vice President of Clinical Development. In this role, McQuillan planned, implemented and managed the clinical regulatory strategy to support European, U.S., Chinese and Japanese submissions for regulatory clearance of the company's computer-aided detection medical image analysis products.

"McQuillan's knowledge and experience in successfully guiding a company from R&D through regulatory trials and all the way through to commercialization are the exact qualities we need at this critical juncture of our development," said GlySure CEO Chris Jones. "In addition to leading efforts to secure a CE mark, McQuillan will be working closely with our U.S. trial sites to prepare for U.S. FDA 510(k) regulatory trials."

McQuillan holds a Master of Business Administration from the University of Westminster, London, a Post-graduate Diploma in Management from University of London, and a Diploma in Medical Diagnostic Imaging from Auckland School of Radiography, New Zealand.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
3. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... ... My T Chai, a South African company that creates a number of ... a popular website specializing in sales of nutritional products. , Chai tea is ... It spread across Asia and Africa quickly, and today recipes vary from region to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As a former ... a thousand words. The good news for single women is that she put all ... is available on April 25th. Joan's insight, personal experiences and sparkling sense of humor ...
(Date:4/24/2017)... ... April 24, 2017 , ... A new global study of ... student well-being has seriously declined. "When disenfranchised youth from the heart of our ... State to turn the historic multi-ethnic and multi-religious powerhouses of the Middle East ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
Breaking Medicine News(10 mins):